Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran; Horvath, L; Rettig, M; Fizazi, K; Lolkema, MP; Dorff, TB; Greil, R; Machiels, JPH; Autio, KA; Rottey, S; Adra, N; Garje, R; Roncolato, F; Tagawa, ST; Shariat, SF; Salvati, M; Poon, S; Kouros-Mehr, H

View this publication in the PUBMED database